- Unum Therapeutics (NASDAQ:UMRX) announces its anticipated milestones for 2019.
- ACTR707 + rituximab in r/r NHL: The Company completed the dose escalation phase of ATTCK-20-03, testing ACTR707 in combination with rituximab to treat patients with relapsed/refractory B cell non-Hodgkin lymphoma. Preliminary data and results are expected in 2019.
- ACTR087 + SEA-BCMA in r/r multiple myeloma: Clinical data from dose escalation study of ACTR087 and SEA-BCMA in ATTCK-17-01 anticipated in 2019.
- ACTR707 + trastuzumab in HER2+ advanced cancers: Enroll and dose patients in Unum’s first ACTR T cell study in solid tumors, ATTCK-34-01.
- ACTR087 + rituximab in r/r NHL: Complete enrollment in ATTCK-20-2, a Phase I clinical trial evaluating safety and anti-lymphoma activity of ACTR087 in combination with rituximab in patients with relapsed or refractory B cell NHL, and report data from the trial.
- Now read: Matinas Biopharma appoints Keith A. Kucinski as CFO
Original article